MYLAN-TERBINAFINE 250 MG
TERBINAFINE (TERBINAFINE HYDROCHLORIDE) : 250 MG · DIN 02242503 · MYLAN PHARMACEUTICALS ULC
Health Canada status: CANCELLED POST MARKET
What is MYLAN-TERBINAFINE?
MYLAN-TERBINAFINE 250 MG contains TERBINAFINE (TERBINAFINE HYDROCHLORIDE) : 250 MG. It is listed in the Health Canada Drug Product Database under DIN 02242503, held by MYLAN PHARMACEUTICALS ULC, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 09-Jan-2017. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02242503 |
|---|---|
| Brand name | MYLAN-TERBINAFINE |
| Generic / active ingredient | TERBINAFINE (TERBINAFINE HYDROCHLORIDE) : 250 MG |
| Manufacturer | MYLAN PHARMACEUTICALS ULC |
| Strength | 250 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | D01BA02 TERBINAFINE |
| AHFS class | 84:08.00 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 09-Jan-2017 |
| Original market date | 2001-06-01 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code D01BA02 TERBINAFINE. 6 of 22 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-TERBINAFINE | 250 MG | TABLET | APOTEX INC | MARKETED | DIN 02239893 |
| AURO-TERBINAFINE | 250 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02320134 |
| PMS-TERBINAFINE | 250 MG | TABLET | PHARMASCIENCE INC | MARKETED | DIN 02294273 |
| TERBINAFINE | 250 MG | TABLET | SIVEM PHARMACEUTICALS ULC | MARKETED | DIN 02385279 |
| TERBINAFINE-250 | 250 MG | TABLET | PRO DOC LIMITEE | MARKETED | DIN 02242735 |
| TEVA-TERBINAFINE | 250 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 02254727 |
| AURO-TERBINAFINE | 125 MG | TABLET | AURO PHARMA INC | CANCELLED PRE MARKET | DIN 02320126 |
| DOM-TERBINAFINE | 250 MG | TABLET | DOMINION PHARMACAL | CANCELLED POST MARKET | DIN 02299275 |
| JAMP-TERBINAFINE | 250 MG | TABLET | JAMP PHARMA CORPORATION | CANCELLED POST MARKET | DIN 02357070 |
| LAMISIL | 250 MG | TABLET | NOVARTIS PHARMACEUTICALS CANADA INC | CANCELLED POST MARKET | DIN 02031116 |
Who else supplies TERBINAFINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. TERBINAFINE appears in 1580 registered pack listings across 13 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.